Prestige Consumer Healthcare (PBH) Total Non-Current Liabilities (2013 - 2026)
Prestige Consumer Healthcare (PBH) posted quarterly Total Non-Current Liabilities of $1.7 billion for Q4 2025, up 8.04% year-over-year from $1.5 billion in Q4 2024, and up 2.95% quarter-over-quarter from $1.6 billion in Q3 2025.
Prestige Consumer Healthcare (PBH) Total Non-Current Liabilities (2013 - 2026) Analysis & Trends
Prestige Consumer Healthcare's Total Non-Current Liabilities history runs 13 years deep, the most recent figure standing at $1.7 billion for Q4 2025.
- In Q4 2025, Total Non-Current Liabilities rose 8.04% year-over-year to $1.7 billion; the TTM figure through Dec 2025 stood at $1.7 billion (up 8.04% YoY), while the FY2025 annual figure was $1.6 billion, down 5.57% from the prior year.
- Total Non-Current Liabilities for Q4 2025 stood at $1.7 billion, up from $1.6 billion in the prior quarter.
- The five-year high for Total Non-Current Liabilities was $2.2 billion in Q3 2021, with the low at $1.5 billion in Q4 2024.
- The 5-year median for Total Non-Current Liabilities is $1.8 billion (2023), against an average of $1.8 billion.
- The sharpest annual moves came in 2023 and 2025: Total Non-Current Liabilities dropped 15.76% in 2023, then rose 8.04% in 2025.
- Prestige Consumer Healthcare's Total Non-Current Liabilities stood at $2.1 billion in 2021, then decreased by 3.69% to $2.1 billion in 2022, then decreased by 15.76% to $1.7 billion in 2023, then slipped by 11.23% to $1.5 billion in 2024, then increased by 8.04% to $1.7 billion in 2025.
- Business Quant data shows PBH's Total Non-Current Liabilities at $1.7 billion in Q4 2025, $1.6 billion in Q3 2025, and $1.6 billion in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.94 Bn | 42.97 Bn | - | -13.28 Bn |
| 2 | Teva Pharmaceutical Industries | 42.95 Bn | 39.30 Bn | 2.15 Bn | 16.45 Bn |
| 3 | Zoetis | 31.58 Bn | 29.90 Bn | 1.05 Bn | 11.64 Bn |
| 4 | Takeda Pharmaceutical | 28.63 Bn | 22.83 Bn | 5.10 Bn | 33.50 Bn |
| 5 | United Therapeutics | 22.16 Bn | 19.49 Bn | 683.80 Mn | 607.80 Mn |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn | 18.76 Bn |
| 7 | Neurocrine Biosciences | 15.53 Bn | 15.14 Bn | 935.80 Mn | 1.37 Bn |
| 8 | Elanco Animal Health | 11.76 Bn | 11.23 Bn | 798.00 Mn | 6.42 Bn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.95 Bn | - | 334.00 Mn |
| 10 | Prestige Consumer Healthcare | 2.44 Bn | 2.37 Bn | - | 1.60 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.60 Bn |
| Dec 31, 2025 | 1.66 Bn |
| Sep 30, 2025 | 1.61 Bn |
| Jun 30, 2025 | 1.57 Bn |
| Mar 31, 2025 | 1.56 Bn |
| Dec 31, 2024 | 1.54 Bn |
| Sep 30, 2024 | 1.58 Bn |
| Jun 30, 2024 | 1.62 Bn |
| Mar 31, 2024 | 1.65 Bn |
| Dec 31, 2023 | 1.73 Bn |
| Sep 30, 2023 | 1.79 Bn |
| Jun 30, 2023 | 1.86 Bn |
| Mar 31, 2023 | 1.90 Bn |
| Dec 31, 2022 | 2.05 Bn |
| Sep 30, 2022 | 2.05 Bn |
| Jun 30, 2022 | 2.09 Bn |
| Mar 31, 2022 | 2.09 Bn |
| Dec 31, 2021 | 2.13 Bn |
| Sep 30, 2021 | 2.21 Bn |
| Jun 30, 2021 | 2.13 Bn |